Skip to main content
Home
FULL MENU Close Menu
Home
Home

Jennifer Kelly Shepphird

News

NRAS mutations predict immunotherapy outcomes in melanoma patients

Author:
Jennifer Kelly Shepphird
Publish date: March 3, 2015

Key clinical point: Patients with advanced melanoma and mutations in the NRAS gene had better responses to immunotherapy than did those without...

  • Read More

News

Liquid biopsy consistent with tumor biopsy for NSCLC

Author:
Jennifer Kelly Shepphird
Publish date: February 26, 2015

Key clinical point: The EGFR mutation L858R detected in both tissue and cfDNA predicted shorter OS and PFS than did the exon 19 deletion. Major...

  • Read More

News

Oral Bisphosphonates Linked with Lower Risk of Endometrial Cancer

Author:
Jennifer Kelly Shepphird
Publish date: February 23, 2015

Key clinical point: Oral bisphosphonate use was modestly associated with reduced risk of endometrial cancer. Major finding: Risk of endometrial...

  • Read More

News

Oral bisphosphonates linked with lower risk of endometrial cancer

Author:
Jennifer Kelly Shepphird
Publish date: February 23, 2015

Key clinical point: Oral bisphosphonate use was modestly associated with reduced risk of endometrial cancer. Major finding: Risk of endometrial...

  • Read More

News

Bevacizumab fails to improve outcomes for metastatic uterine leiomyosarcoma

Author:
Jennifer Kelly Shepphird
Publish date: February 23, 2015

Key clinical point: Bevacizumab added to gemcitabine-docetaxel did not improve outcomes in patients with uterine leiomyosarcoma. Major finding:...

  • Read More

News

Uterine cancer low in myomectomy with power morcellation

Author:
Jennifer Kelly Shepphird
Publish date: February 19, 2015

Key clinical point: Among women who underwent myomectomy, the prevalence of cancers was low but increased with age. Major finding: Rates of...

  • Read More

News

Bevacizumab plus ET failed to improve PFS in HER2-negative, HR-positive BC

Author:
Jennifer Kelly Shepphird
Publish date: February 17, 2015

Key clinical point: In women with HER2-negative, hormone receptor–positive breast cancer, the addition of bevacizumab to endocrine therapy did not...

  • Read More

News

Time and money spent locating unknown primary tumor site might be better spent on genomic analyses

Author:
Jennifer Kelly Shepphird
Publish date: February 14, 2015

Key clinical point: The resources and time spent to locate the primary tumor site in patients with metastatic unknown primary cancer might be...

  • Read More

News

Overall survival plateaus at 3 years for ipilimumab-treated melanoma patients

Author:
Jennifer Kelly Shepphird
Publish date: February 9, 2015

Key clinical point: Ipilimumab-treated advanced melanoma patients alive at 3 years tend to have good long-term outcomes. Major finding: Around...

  • Read More

Pages

  • « first
  • 1
  • 2
  • 3
  • 4

Privacy Policy

Terms of Use

Editorial Policy

Cookie Policy

Ad Policy

Medscape Customer Support

Frequently Asked Questions

 

Advertise with MDedge

See more with MDedge! See our Other Publications

MDedge: Keeping You Informed. Saving You Time.

Copyright  © 2022 Frontline Medical Communications Inc., Newark, NJ, USA. All rights reserved. Unauthorized use prohibited. The information provided is for educational purposes only. Use of this Web site is subject to the medical disclaimer.

Close